{"id":8943,"date":"2026-05-27T22:22:49","date_gmt":"2026-05-27T22:22:49","guid":{"rendered":"https:\/\/prrf.org\/?p=8943"},"modified":"2026-05-27T22:30:37","modified_gmt":"2026-05-27T22:30:37","slug":"gene-therapy-clinical-trials-and-a-fevr-cure-where-the-science-stands-in-2026","status":"publish","type":"post","link":"https:\/\/prrf.org\/ru\/gene-therapy-clinical-trials-and-a-fevr-cure-where-the-science-stands-in-2026\/","title":{"rendered":"Gene Therapy, Clinical Trials, and a FEVR Cure: Where the Science Stands in 2026"},"content":{"rendered":"<div id=\"attachment_8945\" style=\"width: 1034px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8945\" class=\"size-large wp-image-8945\" src=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-1024x683.jpg\" alt=\"PRRF Board Members stand in front of a brick wall at Oakland University.\" width=\"1024\" height=\"683\" srcset=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-1024x683.jpg 1024w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-300x200.jpg 300w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-768x512.jpg 768w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-1536x1024.jpg 1536w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-2048x1366.jpg 2048w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-18x12.jpg 18w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Board-900x600.jpg 900w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><p id=\"caption-attachment-8945\" class=\"wp-caption-text\">The PRRF Family Connection Conference brought together board members who are leading pediatric retina specialists along with families affected by rare pediatric retinal diseases at Oakland University\u2019s Oakland Center in Rochester, Michigan and remotely on Zoom.<\/p><\/div>\n<p><span style=\"font-weight: 400;\">The opportunity to \u201cAsk a Clinician\u201d all your burning questions is one of the most anticipated sessions during the Pediatric Retinal Research Foundation\u2019s annual Family Connection Conference. Each year, participants bring questions that often have been on everyone\u2019s minds. It sparks a dialogue that helps families stay informed but also reminds us how deeply we are connected.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This year we hosted an extraordinary conversation with PRRF President and pediatric retina specialist <\/span><b>Dr. Antonio Capone Jr. <\/b><span style=\"font-weight: 400;\">and our board member<\/span><b> Dr. Matthew Trese.<\/b><span style=\"font-weight: 400;\"> They covered everything from FEVR and ROP to gene therapy, clinical trials, and the future of personalized medicine for pediatric retinal diseases. Dr. Patrick Droste also joined to share decades of expertise on visual rehabilitation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Below are the highlights.<\/span><a href=\"https:\/\/youtu.be\/teWRcGVSTtY?si=_xcnjNbyXtHRzCPb\"> <b>Watch the full Q&amp;A session on YouTube \u2192<\/b><\/a><\/p>\n<h2><b>FEVR (Familial Exudative Vitreoretinopathy): Retinal Tears, Treatment &amp; Genetic Testing<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The session opened with a question from a participant on Zoom, asking whether retinal tears are a normal finding in young adults with FEVR.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Capone explained that in the United States, FEVR almost universally causes <\/span><i><span style=\"font-weight: 400;\">tractional<\/span><\/i><span style=\"font-weight: 400;\"> retinal detachments, driven by scar tissue contracting on the retina,\u00a0 not tears. However, in parts of Asia, a combination of both traction and tears is more common, which has even led researchers in Japan to propose different classification systems for FEVR.<\/span><\/p>\n<blockquote><p><b>\ud83d\udca1 Key Insight:<\/b><span style=\"font-weight: 400;\"> If your child with FEVR in the US has retinal tears, Dr. Capone recommends discussing whether another condition, such as high myopia (nearsightedness), might also be contributing.<\/span><\/p><\/blockquote>\n<h3><\/h3>\n<h3><b>Treatment Options for FEVR Retinal Tears and Holes<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Dr. Trese walked the audience through how tears and holes are managed, depending on how early they&#8217;re caught:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Prophylactic laser<\/b><span style=\"font-weight: 400;\"> can treat at-risk areas of the retina <\/span><i><span style=\"font-weight: 400;\">before<\/span><\/i><span style=\"font-weight: 400;\"> a hole or tear develops in patients with familial exudative vitreoretinopathy.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">If a hole is caught <\/span><b>before fluid accumulates<\/b><span style=\"font-weight: 400;\">, laser or cryotherapy (a freezing treatment) can seal the retina in place, preventing a detachment.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">If fluid has already caused a <\/span><b>retinal detachment<\/b><span style=\"font-weight: 400;\">, the fluid must first be drained, the retina repositioned, and then the weld applied.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In some cases, a <\/span><b>scleral buckle<\/b><span style=\"font-weight: 400;\"> (an external support device) may also be needed.<\/span><\/li>\n<\/ul>\n<h3><\/h3>\n<h3><b>Why Genetic Testing Matters for Every FEVR Family<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Both doctors were emphatic: <\/span><b>genetic testing is essential for FEVR patients<\/b><span style=\"font-weight: 400;\">, even if the results don&#8217;t always return positive. Knowing the specific gene involved helps predict the clinical course, shapes how closely a patient should be followed, and can reveal whether siblings or parents also carry the gene,\u00a0 even if they have perfectly normal vision.<\/span><\/p>\n<blockquote><p><b>\ud83d\udca1 Family Spotlight:<\/b><span style=\"font-weight: 400;\"> It&#8217;s not uncommon for a child to have a severe FEVR presentation while the parent who passed on the gene has completely normal eyesight. This is called <\/span><i><span style=\"font-weight: 400;\">phenotypic variability<\/span><\/i><span style=\"font-weight: 400;\">,\u00a0 and it&#8217;s why screening the whole family matters.<\/span><\/p><\/blockquote>\n<h2><\/h2>\n<h2><b>Is There a Cure for FEVR?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This question came in from the online audience. The doctors gave a thoughtful, honest answer, and it&#8217;s one that many in our community have been wondering about online.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Capone reframed the question using a powerful analogy: just as &#8220;cancer&#8221; is not one disease but hundreds, FEVR (familial exudative vitreoretinopathy) is not one disease either. Many different genetic mutations can produce the same clinical findings. Each may ultimately require its own targeted fix.<\/span><\/p>\n<blockquote><p><b>&#8220;There probably isn&#8217;t going to be <\/b><b><i>a<\/i><\/b><b> cure for FEVR. There are going to be a variety of therapeutic options based on the genetic basis of each individual case.&#8221;<\/b><span style=\"font-weight: 400;\"> &#8211; Dr. Tony Capone<\/span><\/p><\/blockquote>\n<p><span style=\"font-weight: 400;\">The good news: the science of gene therapy for pediatric retinal diseases is advancing at an extraordinary pace. While there are no current clinical trials for FEVR gene therapy specifically, it absolutely has a genetic basis that makes it a strong candidate for future treatment. And as Dr. Capone noted, the cost of developing personalized therapies is coming down.<\/span><\/p>\n<h2><\/h2>\n<h2><b>ROP (Retinopathy of Prematurity): What Families Need to Know at Every Age<\/b><\/h2>\n<div id=\"attachment_8947\" style=\"width: 1034px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8947\" class=\"size-large wp-image-8947\" src=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-1024x683.jpg\" alt=\"Room in Oakland University with two rows of tables, individuals sitting behind tables in various professional attire have their hands raised.\" width=\"1024\" height=\"683\" srcset=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-1024x683.jpg 1024w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-300x200.jpg 300w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-768x512.jpg 768w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-1536x1025.jpg 1536w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-2048x1366.jpg 2048w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-18x12.jpg 18w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Hands-Raised-900x600.jpg 900w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><p id=\"caption-attachment-8947\" class=\"wp-caption-text\">Families came ready with questions! Hands went up throughout the session as the conversation moved from FEVR to ROP, Best disease, Stickler syndrome, and beyond.<\/p><\/div>\n<h3><\/h3>\n<h3><b>Adult ROP Is Real and Under-recognized<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">One audience member asked whether retinal issues continue to appear in adults who were treated for ROP as premature infants. The answer: <\/span><b>yes, and this is a critically important topic<\/b><span style=\"font-weight: 400;\"> as premature infant survival rates have dramatically improved.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Adults with a history of retinopathy of prematurity can experience:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Retinal holes or tears, sometimes as early as adolescence<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reactivation of abnormal blood vessels that leak fluid or lipid into the center of vision<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Slowly developing retinal detachments that can go unnoticed for years<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Dr. Capone shared the story of a valedictorian who had spontaneously regressed ROP as an infant, never treated, and who came in as a young adult with a retinal detachment that had been progressing. He only noticed when it split his central vision.<\/span><\/p>\n<blockquote><p><b>\ud83d\udca1 Critical Reminder for ROP Families:<\/b><span style=\"font-weight: 400;\"> Patients with a history of ROP should be followed by a retina specialist <\/span><b>for life<\/b><span style=\"font-weight: 400;\">. Detachments can develop slowly and without obvious symptoms, even in otherwise healthy, high-functioning young adults.<\/span><\/p><\/blockquote>\n<h3><b>Laser vs. Injection: A Nuanced Answer<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Dr. Trese addressed the shift in how ROP is treated in the NICU. Anti-VEGF injections (medications injected into the eye) have become more common in recent years because they&#8217;re easier to administer and less stressful for fragile newborns. But he was direct: <\/span><b>laser remains the gold standard in his opinion.<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Children treated with injections alone, without laser follow-up, can develop holes in peripheral areas of the retina that never developed proper blood vessels, and may need laser anyway down the road.<\/span><\/p>\n<blockquote><p><b>\ud83d\udca1 For ROP Parents:<\/b><span style=\"font-weight: 400;\"> If your child was treated with an injection for retinopathy of prematurity, ask your doctor whether follow-up laser or ongoing monitoring of the peripheral retina is part of the plan.<\/span><\/p><\/blockquote>\n<h2><\/h2>\n<h2><b>Patching: It&#8217;s Never Too Late At Any Age<\/b><\/h2>\n<div id=\"attachment_8949\" style=\"width: 1034px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8949\" class=\"wp-image-8949 size-large\" src=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-1024x683.jpg\" alt=\"An individual with a dark shirt and name tag reading Charlene stands next to another individual wearing a suit. They are both smiling warmly. The atmosphere is professional.\" width=\"1024\" height=\"683\" srcset=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-1024x683.jpg 1024w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-300x200.jpg 300w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-768x512.jpg 768w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-1536x1024.jpg 1536w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-2048x1366.jpg 2048w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-18x12.jpg 18w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Trese-Charlene-900x600.jpg 900w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><p id=\"caption-attachment-8949\" class=\"wp-caption-text\">Charlene, a PRRF collaborator in the area of vision rehabilitation, poses with Dr. Trese.<\/p><\/div>\n<p><span style=\"font-weight: 400;\">One of the most memorable moments of the entire Q&amp;A came from <\/span><b>Dr. Patrick Droste<\/b><span style=\"font-weight: 400;\">, a decades-long collaborator of Dr. Michael Trese and former PRRF board member,\u00a0 who pushed back firmly on a common myth: that patching only works in young children.<\/span><\/p>\n<blockquote><p><b>&#8220;It is never too late to patch. Ever.&#8221;<\/b><span style=\"font-weight: 400;\"> &#8211; Dr. Patrick Droste<\/span><\/p><\/blockquote>\n<p><span style=\"font-weight: 400;\">Dr. Droste patches patients of all ages, including adults after retinal reattachment surgery, and consistently sees improved outcomes. His approach is practical and patient-centered:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Start small.<\/b><span style=\"font-weight: 400;\"> Even 20\u201330 minutes in the office to let the child and family get comfortable.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Adjust to the child.<\/b><span style=\"font-weight: 400;\"> The right amount of patching depends entirely on the individual.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Trust the process.<\/b><span style=\"font-weight: 400;\"> Every minute of patching reactivates retinal neurons and brain pathways that may have been dormant since the detachment.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Dr. Trese reinforced this: during his training, he would look at a severely distorted eye and assume the child could barely see, only to be told they were 20\/100 or 20\/200, in large part because parents had done the hard work of patching consistently.<\/span><\/p>\n<p><b>\ud83c\udfa7 Want to learn more?<\/b><span style=\"font-weight: 400;\"> PRRF has a full podcast episode dedicated to patching. Visit<\/span> <a href=\"https:\/\/prrf.org\/ru\/the-power-of-eye-patching-a-mother-daughter-story-with-cathy-and-mackenzie-thompson\/\"><b>this link<\/b><\/a><span style=\"font-weight: 400;\"> to listen.<\/span><\/p>\n<h2><\/h2>\n<h2><b>Best Disease Across Three Generations: Understanding Why the Same Gene Looks Different<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">An audience member asked one of the most emotionally resonant questions of the day: why does Best disease look so different across generations in the same family: a grandmother diagnosed in her 20s, a father with minimal vision loss, and a 5-year-old son already receiving injections?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">&#8220;It seems so random,&#8221; she said. &#8220;Is it?&#8221;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Trese and Dr. Capone explained <\/span><b>phenotypic variability<\/b><span style=\"font-weight: 400;\">: the same gene can produce dramatically different presentations of disease, even in the same family. The reasons aren&#8217;t fully understood yet, but likely involve complex interactions between multiple genes and a field called <\/span><b>epigenetics<\/b><span style=\"font-weight: 400;\">, where genes can essentially be switched on or off.<\/span><\/p>\n<blockquote><p><b>\ud83d\udca1 Research Opportunity:<\/b><span style=\"font-weight: 400;\"> There is an active clinical trial for Best disease gene therapy at the <\/span><b>Cincinnati Eye Institute<\/b><span style=\"font-weight: 400;\">, led by Dr. Robert Sisk. Families dealing with Best disease are encouraged to ask their physician about eligibility.<\/span><\/p><\/blockquote>\n<h2><\/h2>\n<h2><b>Stickler Syndrome: Surgical Advances While Genetic Research Grows<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">When it comes to Stickler syndrome, genetic therapy is not available yet. But researchers are actively working on it. The Pediatric Retinal Research Lab BioBank is being used to compile patient data and identify subtypes of Stickler and related vitreoretinal degenerations, many of which don&#8217;t yet have formal names in the medical literature.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In the meantime, surgical management has meaningfully advanced. Dr. Capone highlighted the use of <\/span><b>methotrexate<\/b><span style=\"font-weight: 400;\"> (an anti-scarring medication originally developed for cancer) during and after retinal detachment surgery in Stickler patients. Because children with Stickler face higher risk of a complication called <\/span><b>proliferative vitreoretinopathy (PVR)<\/b><span style=\"font-weight: 400;\">, where scar tissue forms inside the eye and causes repairs to fail, methotrexate has become an important tool for improving surgical outcomes over the last decade.<\/span><\/p>\n<h2><\/h2>\n<h2><b>Clinical Trials for Pediatric Retinal Diseases: Should Your Family Consider One?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-8950\" src=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-1024x378.jpg\" alt=\"Wide angle of the room during the Dr Q&amp;A with Drs Capone and Trese at the front of the room and a large audience listening attentively in a university room.\" width=\"1024\" height=\"378\" srcset=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-1024x378.jpg 1024w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-300x111.jpg 300w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-768x284.jpg 768w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-1536x567.jpg 1536w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-2048x756.jpg 2048w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Dr-QA-1-18x7.jpg 18w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Capone gave a clear, accessible breakdown of how clinical trials work for families considering participation:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Phase 1 \u2014 Safety:<\/b><span style=\"font-weight: 400;\"> Small group, focused entirely on whether the treatment is safe.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Phase 2 \u2014 Dosing:<\/b><span style=\"font-weight: 400;\"> Larger group, testing a range of doses to identify effectiveness.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Phase 3 \u2014 Confirmation:<\/b><span style=\"font-weight: 400;\"> Large population, confirming safety and efficacy at the optimal dose.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Phase 4 \u2014 Real World:<\/b><span style=\"font-weight: 400;\"> Tracking outcomes after FDA approval, outside the trial setting.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">His bottom line: <\/span><b>clinical trials are designed with patient safety as the absolute top priority.<\/b><span style=\"font-weight: 400;\"> All risks must be fully disclosed upfront. The phased structure exists specifically to catch problems before they reach a broad patient population.<\/span><\/p>\n<blockquote><p><b>\u26a0\ufe0f A Word of Caution:<\/b><span style=\"font-weight: 400;\"> Dr. Capone noted that unregulated treatments given outside the clinical trial framework, such as stem cell injections into the eye, have caused serious, irreversible harm. The structure of a clinical trial is a protection, not red tape.<\/span><\/p><\/blockquote>\n<h2><\/h2>\n<h2><b>Gene Therapy for Pediatric Retinal Disease: The Horizon Is Getting Closer<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Dr. Trese highlighted the remarkable pace of change. Luxturna (for RPE65 mutations in Leber congenital amaurosis) has shown life-changing results and a new clinical trial for the most common form of LCA (CEP290) was recently announced.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The broader takeaway: the disease labels we&#8217;ve used for decades (FEVR, LCA, RP, Best disease) are increasingly being revealed as umbrella terms for many genetically distinct conditions. Personalized genetic medicine is the future of treatment for pediatric retinal diseases.<\/span><\/p>\n<h2><b>The Real Goal: Function, Independence, and a Full Life<\/b><\/h2>\n<div id=\"attachment_8948\" style=\"width: 1034px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8948\" class=\"size-large wp-image-8948\" src=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-1024x683.jpg\" alt=\"Four members of the PRRF staff stand posing in the hallway at Oakland University. They are dressed professionally.\" width=\"1024\" height=\"683\" srcset=\"https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-1024x683.jpg 1024w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-300x200.jpg 300w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-768x512.jpg 768w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-1536x1025.jpg 1536w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-2048x1366.jpg 2048w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-18x12.jpg 18w, https:\/\/prrf.org\/wp-content\/uploads\/2026\/05\/Staff-900x600.jpg 900w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><p id=\"caption-attachment-8948\" class=\"wp-caption-text\">The PRRF team behind the scenes: working to make sure every family who walks through our doors feels seen, supported, and informed.<\/p><\/div>\n<p><span style=\"font-weight: 400;\">The session closed with a powerful reflection from an online audience member working in vision rehabilitation. She asked: &#8220;When do you know it&#8217;s time to shift from <\/span><i><span style=\"font-weight: 400;\">getting the patient to see<\/span><\/i><span style=\"font-weight: 400;\"> \u043d\u0430 <\/span><i><span style=\"font-weight: 400;\">getting the patient to function<\/span><\/i><span style=\"font-weight: 400;\">?&#8221;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Trese\u2019s answer: it&#8217;s never one or the other. The team always has function in mind, but timing matters. Introducing orientation and mobility training or cane use too early can feel to a patient like giving up. The goal is to keep the door open, raise the topic gently and consistently, and meet patients where they are.<\/span><\/p>\n<blockquote><p><b>&#8220;When you&#8217;re ready, we know the right people to send you to.&#8221;<\/b><span style=\"font-weight: 400;\"> &#8211; Dr. Matt Trese<\/span><\/p><\/blockquote>\n<h2><b>Watch the Full Session<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This recap covers the highlights, but there&#8217;s so much more in the full conversation.<\/span><\/p>\n<p><a href=\"https:\/\/youtu.be\/teWRcGVSTtY?si=_xcnjNbyXtHRzCPb\"><b>Watch the complete Q&amp;A on YouTube \u2192<\/b><\/a><\/p>\n<p>&#8212;<\/p>\n<p><i><span style=\"font-weight: 400;\">The responses shared at this event are educational in nature and are not a substitute for individualized medical advice. Please consult your care team with questions specific to your child.<\/span><\/i><\/p>\n<p><i><span style=\"font-weight: 400;\">Visit<\/span><\/i><a href=\"https:\/\/prf.org\/\"> <i><span style=\"font-weight: 400;\">PRRF.org<\/span><\/i><\/a><i><span style=\"font-weight: 400;\"> to explore our podcast library, learn about our BioBank, and find resources for families living with pediatric retinal diseases.<\/span><\/i><\/p>\n<p><b>Tags: <\/b><span style=\"font-weight: 400;\">FEVR, familial exudative vitreoretinopathy, FEVR retina, ROP, retinopathy of prematurity, adult ROP, Best disease, Stickler syndrome, LCA, Leber congenital amaurosis, gene therapy pediatric retina, retinal detachment children, pediatric retinal diseases, patching amblyopia, low vision children, smart glasses visually impaired, glasses for visually impaired, norrie disease, x-chromosomal retinoschisis, PRRF, Pediatric Retinal Research Foundation, clinical trials retinal disease, visually impaired children, glasses for blind people, vision impaired glasses<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Key Takeaways from PRRF&#8217;s Family Connection Conference Clinician Q&#038;A.<\/p>","protected":false},"author":1,"featured_media":8946,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","om_disable_all_campaigns":false,"footnotes":""},"categories":[43,36],"tags":[80,81,95,77,32,78,85,97,91,83,84,89,29,88,87,94,93,86,79,30,90,82,98,96,92],"class_list":{"0":"post-8943","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-articles","8":"category-blog","9":"tag-adult-rop","10":"tag-best-disease","11":"tag-clinical-trials-retinal-disease","12":"tag-familial-exudative-vitreoretinopathy","13":"tag-fevr","14":"tag-fevr-retina","15":"tag-gene-therapy-pediatric-retina","16":"tag-glasses-for-blind-people","17":"tag-glasses-for-visually-impaired","18":"tag-lca","19":"tag-leber-congenital-amaurosis","20":"tag-low-vision-children","21":"tag-norrie-disease","22":"tag-patching-amblyopia","23":"tag-pediatric-retinal-diseases","24":"tag-pediatric-retinal-research-foundation","25":"tag-prrf","26":"tag-retinal-detachment-children","27":"tag-retinopathy-of-prematurity","28":"tag-rop","29":"tag-smart-glasses-visually-impaired","30":"tag-stickler-syndrome","31":"tag-vision-impaired-glasses","32":"tag-visually-impaired-children","33":"tag-x-chromosomal-retinoschisis"},"_links":{"self":[{"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/posts\/8943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/comments?post=8943"}],"version-history":[{"count":6,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/posts\/8943\/revisions"}],"predecessor-version":[{"id":8956,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/posts\/8943\/revisions\/8956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/media\/8946"}],"wp:attachment":[{"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/media?parent=8943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/categories?post=8943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prrf.org\/ru\/wp-json\/wp\/v2\/tags?post=8943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}